Memo Therapeutics is a late-stage biotech company that has raised CHF 25M in a Series C funding round to develop its antibody, AntiBKV, and advance its existing antibody pipeline.

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.

LimmaTech Biologics is a Swiss company that develops vaccines against multidrug-resistant bacterial infections, with a focus on shigellosis and gonorrhea, using E. coli expression systems.